Tonix Pharmaceuticals Holding Corp.
TNXP
$16.88
-$0.42-2.43%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.58M | 2.82M | 2.21M | 2.48M | 3.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.58M | 2.82M | 2.21M | 2.48M | 3.78M |
| Cost of Revenue | 1.18M | 1.56M | 3.37M | 1.66M | 2.37M |
| Gross Profit | 1.40M | 1.27M | -1.16M | 822.00K | 1.41M |
| SG&A Expenses | 15.58M | 7.71M | 7.50M | 9.31M | 11.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.06M | 18.38M | 20.57M | 23.83M | 31.11M |
| Operating Income | -22.48M | -15.55M | -18.36M | -21.35M | -27.33M |
| Income Before Tax | -22.11M | -14.21M | -78.78M | -14.94M | -27.32M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.11M | -14.21M | -78.78M | -14.94M | -27.32M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.11M | -14.21M | -78.78M | -14.94M | -27.32M |
| EBIT | -22.48M | -15.55M | -18.36M | -21.35M | -27.33M |
| EBITDA | -21.51M | -15.04M | -17.39M | -20.38M | -25.83M |
| EPS Basic | -9.77 | -22.88 | -1.93K | -591.06 | -2.18K |
| Normalized Basic EPS | -6.10 | -14.30 | -303.22 | -369.41 | -- |
| EPS Diluted | -9.77 | -22.88 | -1.93K | -591.06 | -2.18K |
| Normalized Diluted EPS | -6.10 | -14.30 | -303.22 | -369.41 | -- |
| Average Basic Shares Outstanding | 2.26M | 621.20K | 40.90K | 25.30K | -- |
| Average Diluted Shares Outstanding | 2.26M | 621.20K | 40.90K | 25.30K | 12.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
